TEMA ETFs

Founder and CEO Maurits Pot leads portfolio construction, supported by a research team conducting fundamental analysis on each name. Pot brought equity derivatives and cross-asset structuring experience from Goldman Sachs and served as Deputy CEO at Amundi's US asset management business before launching TEMA in 2023. The firm's active ETF registrations mean PMs have full discretion to deviate from any reference benchmark when underlying fundamentals warrant.

TEMA ETFs are actively managed and typically hold 20-40 names, whereas most thematic ETFs use passive, rules-based indexes that rebalance on a fixed schedule. The active structure lets TEMA exit positions when the investment thesis breaks rather than waiting for the next index reconstitution. Each fund concentrates risk around a single thesis — oncology drug development, US industrial reshoring, or AI-driven genomics discovery — rather than offering diversified exposure across an entire sector.

The TEMA American Reshoring ETF invests in US-listed companies expected to benefit from the relocation of critical supply chains back to North America. Holdings span industrial automation providers, semiconductor manufacturers building domestic fabrication capacity, and logistics firms positioned along re-shored manufacturing corridors. The fund is actively managed, meaning the portfolio team can adjust exposure as policy incentives like the CHIPS Act and Inflation Reduction Act evolve.

TEMA's 2023 launch timing reflects a thesis that the thematic ETF category needed a reset. The 2022 selloff exposed weaknesses in passive thematic structures, where funds had been forced buyers of momentum names at peak valuations. TEMA entered with an active mandate precisely to avoid that problem — the team can size positions based on valuation discipline rather than index weight and can hold cash or move to higher-conviction names during drawdowns. The firm's small, deliberate product shelf also contrasts with the volume-over-performance launch strategies of earlier thematic entrants.

TEMA focuses exclusively on public equities through its ETF suite, targeting secular growth themes that cut across traditional GICS sectors. Confirmed coverage areas include oncology therapeutics, cardiovascular and metabolic disease treatment, industrial automation and reshoring, and AI-enabled genomics. The firm has not launched fixed-income, commodity, or multi-asset products, keeping its shelf intentionally narrow around biology and industrial innovation equity strategies.